Hemab Q2 FY26 net loss widens to $24.15 million; R&D expenses rise to $20.34 million

Reuters2026/08/11 11:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Hemab Therapeutics posted a Q2 net loss of $24.2 million, or $0.80 per share, versus a $12.2 million loss a year earlier.
R&D expense rose to $20.3 million from $12.9 million year over year; G&A climbed to $5.7 million from $3.2 million.
Cash, cash equivalents, and marketable securities jumped to $457.5 million from $163.5 million at March 31, boosted by $317.2 million IPO proceeds.
FDA endorsed sutacimig’s GT data package to move into a Phase 3 pivotal trial at 0.2 mg/kg weekly, with initiation planned in 2H 2026.
HMB-003 was unveiled for heavy menstrual bleeding, with first-in-human studies planned for 2H 2026 and initial clinical data targeted for mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hemab Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110700PRIMZONEFULLFEED9807446) on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Hemab Q2 FY26 net loss widens to $24.15 million; R&D expenses rise to $20.34 million

You may also like

Crypto prices